LP-6

• UNSPSC Description:

  LP-6 is a Drug-Linker Conjugates for ADC, and can be used for synthesis of ADCs. LP-6 consists of an Eg5 inhibitor and a linker[1].

• Target Antigen:

  Drug-Linker Conjugates for ADC

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lp-6.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC([C@H](C1=NC(C2=CC(F)=CC=C2F)=CN1CC3=CC=CC=C3)N(C[C@H]4[C@H](CNC4)F)C([C@@H](O)C)=O)(CC(NCCN5C(C=CC5=O)=O)=O)C

• Molecular Weight:

  694.74

• References & Citations:

  [1]Karpov AS, et al. Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization. ACS Med Chem Lett. 2019 Dec 3;10(12):1674-1679.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1629736-79-3